LITERATURE
符合新入排标准的活动候选
仅显示 v3 复核后仍在自动处理队列中的候选论文。 共 1883 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.J Immunother Cancer | PMID 42648750PMC13536168 | 2026-Aug-26 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.Lancet | PMID 42624156无 PMCID | 2026-Aug-22 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Adjuvant Therapy for Resected Adenocarcinoma of the Pancreas.Am J Clin Oncol | PMID 42622289无 PMCID | 2026-Aug-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.Signal Transduct Target Ther | PMID 42586967PMC13470399 | 2026-Aug-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.Nat Commun | PMID 42706268PMC13550555 | 2026-Aug-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.BMC Cancer | PMID 42563153PMC13449588 | 2026-Aug-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Comparison of Sex-Specific Treatment Outcomes in Clinical Trials and Subsequent Real-World Data on Systemic Therapies for Urothelial Carcinoma: A Systematic Review.Aktuelle Urol | PMID 42551842无 PMCID | 2026-Aug-04 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703).JAMA | PMID 42545685PMC13434973 | 2026-Aug-03 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: a phase III trial and biomarker analyses.J Natl Cancer Cent | PMID 42630515PMC13494611 | 2026-Aug | 0.99 | Eligible original Phase III randomized oncology trial of a drug-containing regimen with OS/PFS time-to-event efficacy results. | 待处理 |
| Trastuzumab deruxtecan plus pertuzumab as a substantial advancement in previously untreated patients with HER2-positive metastatic breast cancer.Eur Rev Med Pharmacol Sci | PMID 42677694无 PMCID | 2026-Aug | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Postmastectomy radiation therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a retrospective exploratory cohort analysis of the adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO) trial [BIG 2-06/NCCTG N063D (Alliance)].EClinicalMedicine | PMID 42541182PMC13427515 | 2026-Aug | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10.Future Oncol | PMID 42535874无 PMCID | 2026-Aug | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet Haematol | PMID 42532067无 PMCID | 2026-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| RATIONALE-303: Long-Term Outcomes of Tislelizumab in Previously Treated Advanced/Metastatic NSCLC.JTO Clin Res Rep | PMID 42529140PMC13416824 | 2026-Aug | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Automated measurement of CD8+ T-cell distribution at the tumor epithelial-stromal interface is associated with NSCLC immunotherapy benefit and transcriptomic pathways.J Pathol Inform | PMID 42518513PMC13382319 | 2026-Aug | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.Lancet Oncol | PMID 42508427无 PMCID | 2026-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.Lancet Oncol | PMID 42508432无 PMCID | 2026-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A novel neoadjuvant immunotherapy confers improved overall survival in oral cancer patients with low tumor PD-L1 expression The IT-MATTERS Clinical trial - Prognostic role of tumor PD-L1 expression.Oral Oncol | PMID 42537452无 PMCID | 2026-Jul-31 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Final analysis of the FeDeriCa phase III study: long-term efficacy, safety and pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, plus chemotherapy, in HER2-positive early breast cancer.ESMO Open | PMID 42537585无 PMCID | 2026-Jul-31 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.JAMA Oncol | PMID 42530945PMC13425239 | 2026-Jul-30 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial.JAMA Oncol | PMID 42530948PMC13425241 | 2026-Jul-30 | 0.95 | The record describes an original Phase 3 randomized trial in human oncology with a drug-containing intervention (TACE) and primary/secondary time-to-event efficacy endpoints (PFS, OS). | 待处理 |
| COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.J Clin Oncol | PMID 42525921无 PMCID | 2026-Jul-29 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826).Blood Adv | PMID 42526889无 PMCID | 2026-Jul-29 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.Eur Urol | PMID 42521517无 PMCID | 2026-Jul-28 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.J Clin Oncol | PMID 42507968无 PMCID | 2026-Jul-27 | 0.95 | The record explicitly describes a phase III randomized trial with a drug intervention and primary/time-to-event endpoints (OS, PFS). The final OS analysis is reported. All required criteria are met. | 待处理 |
| Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42269244无 PMCID | 2026-Jul-26 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.J Clin Oncol | PMID 42497381无 PMCID | 2026-Jul-24 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Time-dependent recurrence patterns after curative resection for stage II/III colorectal cancer: An integrated analysis of four phase III randomized controlled trials (JCOG2310A-S4).Eur J Cancer | PMID 42520593无 PMCID | 2026-Jul-23 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase III Trial.J Clin Oncol | PMID 42492015无 PMCID | 2026-Jul-23 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42485627无 PMCID | 2026-Jul-23 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials.ESMO Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42485700无 PMCID | 2026-Jul-22 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study.ESMO Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42480197无 PMCID | 2026-Jul-21 | 0.95 | The record explicitly describes a phase III randomized trial with a drug intervention, reporting final survival outcomes (OS, PFS) as time-to-event efficacy endpoints. All required criteria are established. | 无 KM 图 |
| Systematic review and adjusted indirect comparison of first-line immune checkpoint inhibitors in metastatic colorectal cancer.Farm Hosp疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42481259无 PMCID | 2026-Jul-21 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial.Biomol Biomed疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42483812无 PMCID | 2026-Jul-21 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| The Role of Locoregional Treatment in Non-Progressive De Novo Metastatic Breast Cancer under Systemic Treatment: A Randomized Controlled Trial (LTMBC).Ann Surg Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42472751无 PMCID | 2026-Jul-20 | 0.95 | Original Phase III randomized trial evaluating locoregional treatment versus systemic therapy in de novo metastatic breast cancer, with primary OS endpoint. The study is drug-containing (systemic therapy is the comparator and maintenance treatment). | 无 KM 图 |
| Design-Outcome Concordance in Targeted-Therapy trials in Non-Small cell lung cancer: a Meta-Research study.J Natl Cancer Inst疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42477876无 PMCID | 2026-Jul-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 3::非 KM 图。 | PMID 42456135PMC13374710 | 2026-Jul-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer.Eur J Cancer | PMID 42492306无 PMCID | 2026-Jul-09 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42418775无 PMCID | 2026-Jul-09 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.Breast Cancer Res Treat疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42420599无 PMCID | 2026-Jul-08 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study).Jpn J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41968990无 PMCID | 2026-Jul-06 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.Signal Transduct Target Ther | PMID 42402625PMC13334029 | 2026-Jul-06 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42384869无 PMCID | 2026-Jul-02 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Superiority of Adjuvant Hyperfractionated Radiotherapy Over Chemotherapy Following Radical Cystectomy.Asian Pac J Cancer Prev | PMID 42522819无 PMCID | 2026-Jul-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41571044无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials.J Thorac Oncol已检查 6 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 flow diagram;Figure 3A:AI 判定为 other;Figure 3B:AI 判定为 other;Figure 4A:AI 判定为 other;另有 1 张未列出。 | PMID 41747891PMC13095140 | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41833903无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Comparing paclitaxel and platinum-based concurrent chemoradiotherapy with short-term adjuvant chemotherapy versus platinum-based monotherapy concurrent chemoradiotherapy in patients with postoperative gastric-type endocervical adenocarcinoma with high-risk factors for recurrence: a multicenter randomized phase III trial.J Gynecol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41834413无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41999978无 PMCID | 2026-Jul | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42025759无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |